A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides.
Levin
A A
AA
Toxicology and Pharmacokinetics, ISIS Pharmaceuticals, Inc., Carlsbad, CA 92008, USA. alevin@isisph.com
D000818:Animals; D001777:Blood Coagulation / Q000187:drug effects; D002477:Cells / Q000187:drug effects / Q000378:metabolism; D003167:Complement Activation / Q000187:drug effects; D017242:Complement Factor H / Q000378:metabolism; D004333:Drug Administration Routes; D016503:Drug Delivery Systems; D000882:Haplorhini; D006801:Humans; D051379:Mice; D009152:Mutagenicity Tests; D009693:Nucleic Acid Hybridization / Q000187:drug effects; D016376:Oligonucleotides, Antisense / Q000008:administration & dosage / Q000097:blood / Q000276:immunology / Q000493:pharmacokinetics* / Q000633:toxicity*; D009928:Organ Specificity / Q000187:drug effects; D011485:Protein Binding / Q000187:drug effects; D012313:RNA / Q000378:metabolism; D051381:Rats; D013873:Thionucleotides / Q000008:administration & dosage / Q000097:blood / Q000276:immunology / Q000493:pharmacokinetics* / Q000633:toxicity*; D014018:Tissue Distribution
C493495:CFH protein, human; D016376:Oligonucleotides, Antisense; D013873:Thionucleotides; D012313:RNA; D017242:Complement Factor H